KBC Group NV Buys 10,068 Shares of UiPath Inc. (NYSE:PATH)

KBC Group NV boosted its stake in UiPath Inc. (NYSE:PATHFree Report) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,880 shares of the healthcare company’s stock after purchasing an additional 10,068 shares during the quarter. KBC Group NV’s holdings in UiPath were worth $1,388,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PATH. Norges Bank bought a new position in shares of UiPath during the fourth quarter worth $165,749,000. Vanguard Group Inc. increased its holdings in shares of UiPath by 7.6% in the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after acquiring an additional 2,673,718 shares in the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of UiPath during the fourth quarter worth about $48,267,000. Glenmede Trust Co. NA lifted its holdings in shares of UiPath by 3,273.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock valued at $26,777,000 after purchasing an additional 1,518,592 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new position in shares of UiPath in the 4th quarter valued at approximately $15,543,000. Institutional investors and hedge funds own 62.50% of the company’s stock.

Analysts Set New Price Targets

PATH has been the topic of a number of research reports. Canaccord Genuity Group cut their price target on shares of UiPath from $30.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, May 31st. Scotiabank reduced their target price on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a research note on Wednesday, May 29th. BMO Capital Markets dropped their price target on UiPath from $28.00 to $14.00 and set a “market perform” rating on the stock in a research note on Monday, June 3rd. Mizuho cut their price target on UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, May 30th. Finally, Barclays decreased their price objective on UiPath from $25.00 to $16.00 and set an “equal weight” rating for the company in a report on Thursday, May 30th. Sixteen analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $18.12.

View Our Latest Report on PATH

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 96,000 shares of company stock worth $2,023,440 over the last ninety days. Insiders own 22.37% of the company’s stock.

UiPath Stock Performance

Shares of NYSE:PATH opened at $12.00 on Friday. UiPath Inc. has a 52-week low of $11.53 and a 52-week high of $27.87. The company has a market capitalization of $6.83 billion, a P/E ratio of -75.00 and a beta of 0.85. The company has a 50-day simple moving average of $18.84 and a 200 day simple moving average of $21.81.

UiPath (NYSE:PATHGet Free Report) last released its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The company had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. As a group, equities analysts forecast that UiPath Inc. will post -0.2 earnings per share for the current year.

About UiPath

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Further Reading

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.